Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.
No news articles found for Arch Therapeutics.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.